GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Compound 17B [WO2023178099]
Compound class:
Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026), in which it is described as a NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome inhibitor with potential as a non-steroidal anti-inflammatory agent. It is one of the structures claimed in Zomagen Biosciences' (now part of Eli Lilly via a previous Ventyx Biosciences merger) patent WO2023178099 [1]. Evidence suggests that parunoflast is likely the INN for the CNS-penetrant NLRP3 inhibitor VTX3232.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Collina J, Bollu V, Yuan S, Nuss J. (2023)
Nlrp3 modulators. Patent number: WO2023178099A1. Assignee: Zomagen Biosciences Ltd. Priority date: 14/03/2023. Publication date: 21/09/2023. |